Investors originally expected the Food and Drug Administration to approve Galvus by Nov. 30 of last year, but the FDA delayed its decision by three months in order to further scrutinize a series of skin reactions seen in primates who had received the drug.

FORBES: Novartis Shares Fall On Report Of Drug Delay